Breaking News

UBC Selects THREAD to Launch New SitePlus Offering

Offers sponsors full-featured central site model with research services and technology to expand access in post-approval research.

By: Kristin Brooks

Managing Editor, Contract Pharma

United BioSource LLC (UBC), a provider of evidence development services, and THREAD, a decentralized research and consulting services provider, have launched SitePlus, a next-generation post-approval research model. SitePlus offers nationwide, direct-to-patient recruitment strategies and aims to reduce the burden of patients and providers participating in late-stage research by combining UBC’s sservices with THREAD’s technology.
 
The alliance enables biopharmaceutical sponsors to contract with UBC as a central research center with investigator and coordinator services. SitePlus connects UBC’s central principal investigator and patient coordinating center expertise with THREAD’s technology platform and consulting services for data capture, telehealth, and patient engagement.
 
The collaboration expands the companies’ enterprise partnership an additional three years to continue supporting UBC’s decentralized research and eCOA solutions for patient-centered research studies to be conducted in the clinic, in the home, and on-the-go.
 
“Traditional site-only research models are not sufficient to meet the growing demands of regulators, payors, and providers to generate evidence that demonstrates the safety and value of treatments,” said UBC President and Chief Executive Officer Bekki Brown. “The THREAD technology platform supports our customer offering by enabling a more flexible approach to patient recruitment and engagement and, ultimately, amplifies the return on evidence generation investment for our clients.”
 
“SitePlus will enable UBC’s customers to expand their geographic footprint for study recruitment and offer their research to a broader population supported by a precision screening process,” said THREAD Co-Founder and CEO John Reites. “We are excited UBC selected us as their partner to enable its new SitePlus offering while aligning with our mission to advance research for everyone, everywhere.”
 

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters